AptarGroup’s Q3 Results Review
<p><a href='https://financialmodelingprep.com/financial-summary/ATR'>AptarGroup, Inc. (NYSE:ATR) </a>reported its Q3 results last week, with revenue growing 9% year-over-year to $825 million.</p>
<p>According to the analysts at Deutsche Bank, the results were below expectations driven by Pharma as the destocking issue in prescription continues to hinder earnings. While it is unclear when the issue will be resolved, the company mentioned positive signs in its consumer healthcare end market. The analysts expect the destocking to continue into Q4 and somewhat into Q1/22. The next quarter’s outlook implies a sequential decline in earnings due to the business mix in the Pharma segment, unfavorable currency, rising inflation and supply chain disruptions.</p>
<p>Analysts at Deutsche Bank lowered their price target on the company’s shares to $148 from $158, while maintaining their buy rating as they believe the Pharma business is undervalued and the company should continue to see recovery in beauty.</p>

NYSE:ATR